Last reviewed · How we verify
NCT06755918
Video Games and Mask Painting on During Nebulizer Application in Children
NA trial testing Control in NEBULIZATION in 66 participants. Participants enrolled and being followed up; not accepting new ones.
15 March 2025
Quick facts
| Lead sponsor | Semra Kose |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 66 |
| Start date | 9 December 2024 |
| Primary completion | 15 March 2025 |
| Estimated completion | 15 June 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Control
- Video game
- Mask painting
Conditions studied
- NEBULIZATION — all drugs for NEBULIZATION →
- Children — all drugs for Children →
Sponsor
Semra Kose
Who can join
Adults 7 to 12, any sex, with NEBULIZATION or Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical features of respiratory system diseases seen in childhood are generally moderate and improve in a short time. Respiratory system diseases are divided into two as upper respiratory system diseases and lower respiratory system diseases. The respiratory tract, from the mouth and nose, which are the upper respiratory tract, to the glottis (nasal mucosa, nasopharynx, oropharynx, sinuses, middle ear tonsils and epiglottis) and the infections that occur in these sections are called upper respiratory tract infections (URTI). Lower respiratory system diseases are considered as tuberculosis, asthma, cystic fibrosis and bronchopulmonary dysplasia. The most common diseases in children are respiratory tract diseases. The diseases that are considered as priorities for each age group vary. According to the Turkish Thoracic Society, the incidence of lower respiratory tract infections (LRTI) between the ages of 0-5 is 29%. According to TUIK 2022 data, upper respiratory tract infections are the most common infectious diseases experienced by children between the ages of 0-6 with a rate of 31.3%, and lower respiratory tract infections are the third with a rate of 6.9%. In children between the ages of 7-14, upper respiratory tract infections are the most common with a rate of 27.1%, and lower respiratory tract infections are the third with a rate of 5.3%.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06755918
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Control
Trials testing the same drug.
- NCT06064604 — Clinical Efficacy of Exoskeleton Assistance for Individuals Post-Stroke · NA · not yet recruiting
- NCT04039386 — Psychosocial Interventions for Young Adults With Hip Pain · NA · not yet recruiting
- NCT07042373 — Effects of Tobacco Abuse Liability-dependent Taxes in the ETM · NA · not yet recruiting
- NCT07512999 — The Effect of Using Nature Sounds and Virtual Reality During the Non-Stress Test · NA · not yet recruiting
- NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
Other Semra Kose trials
Trials by the same sponsor.
- NCT06755931 — The Effect of Quilling Exercise Applied Before Cardiac Catheterization and Angiography · NA · active not recruiting
- NCT06741176 — The Effect of the Message Left by Mothers Whose Babies Are in the Neonatal Intensive Care Unit · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06755918 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Semra Kose
- Last refreshed: 1 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06755918.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing